
|Articles|January 12, 2022
Daily Medication Pearl: Inclisiran (Leqvio) Injection
Author(s)Saro Arakelians, PharmD
Inclisiran treats adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol.
Advertisement
Medication Pearl of the Day: Inclisiran (Leqvio) Injection
Indication: Inclisiran is a small interfering RNA directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Insight:
- Dosing: The recommended dosage of inclisiran, in combination with maximally tolerated statin therapy, is 284 mg administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months.
- Dosage forms: Injection 284 mg/1.5 mL (189 mg/mL) in a single-dose prefilled syringe.
- Adverse events: Common adverse reactions in clinical trials (≥ 3%) are injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity, and dyspnea.
- Mechanism of action: Inclisiran is a double-stranded small interfering ribonucleic acid, conjugated on the sense strand with triantennary N-Acetylgalactosamine to facilitate uptake by hepatocytes. In hepatocytes, inclisiran uses the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.
- Manufacturer: Novartis
Sources:
Advertisement
Related to this article

Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Overton FDA Nomination Withdrawn: What It Means for Pharmacists
2
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
3
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
4
SNO 2026 Roundup: What Longer Follow-Up Means for Targeted Glioma Care
5

